Informace o publikaci

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

Autoři

VAN EIMEREN T. ANTONINI A. BERG D. BOHNEN N. CERAVOLO R. DRZEZGA A. HÖGLINGER G. HIGUCHI M. LEHERICY S. LEWIS S. MONCHI O. NESTOR P. ONDRUS M. PAVESE N. PERALTA M.C. PICCINI P. PINEDA-PARDO J.A. REKTOROVÁ Irena RODRÍGUEZ-OROZ M.

Rok publikování 2019
Druh Článek v odborném periodiku
Časopis / Zdroj Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1016/j.dadm.2019.01.011
Doi http://dx.doi.org/10.1016/j.dadm.2019.01.011
Klíčová slova Biomarker; CDB; CBS; MRI;MSA
Popis Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info